ethyl α-cyanocrotonate | 130508-73-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl α-cyanocrotonate
• 英文别名: ethyl (Z)-2-cyanobut-2-enoate
• CAS: 130508-73-5
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: WIUDWAAJQVNSOH-UTCJRWHESA-N

物化性质

• 沸点：
  71-72 °C(Press: 2.4 Torr)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl α-cyanocrotonate 在 三异丙氧基氯化钛 、 盐酸 作用下， 以 甲醇 为溶剂， 反应 7.17h， 生成 4-Methyl-2-oxo-5-vinyl-tetrahydro-furan-3-carbonitrile
  参考文献：
  名称：

  The anti-selective Michael addition of allylic organometals to ethylidenemalonates and related compounds

  摘要：

  DOI：

  10.1021/jo00250a034

文献信息

• NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND
  申请人：Suzuki Keiko

  公开号：US20120108639A1

  公开（公告）日：2012-05-03

  The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R 1 represents COOH; each R 2 represents an alkyl; each R 3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R 4 , R 5 , R 6 , and R 7 represents H, an alkyl; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B 1 and B 2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.

  本发明提供了一种具有优异的调节血脂水平作用的化合物，其表示为以下通式(I)或其药学上可接受的盐，其中，在一种实施例中，A代表5-成员含氮芳香杂环基；R1代表COOH；每个R2代表烷基；每个R3代表可选取代的苯基，可选取代的苯基烷基；m代表0、1、2或3；n代表0或1；每个R4、R5、R6和R7代表H，烷基；B代表可选取代的萘基，可选取代的芳香杂环基，或由以下公式(II)表示的基团，其中，每个B1和B2代表可选取代的苯基或可选取代的芳香杂环基。
• INHIBITORS OF AKT ACTIVITY
  申请人：Fan Weiming

  公开号：US20120004240A1

  公开（公告）日：2012-01-05

  The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了取代的融合萘啉衍生物，可抑制Akt活性。特别地，所披露的化合物选择性地抑制一种或两种Akt同工型。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要治疗癌症的患者施用该化合物来抑制Akt活性的方法。
• Catel, Jean-Marie; Mollier, Yves, Bulletin de la Societe Chimique de France, 1981, vol. 2, # 3-4, p. 113 - 124
  作者：Catel, Jean-Marie、Mollier, Yves

  DOI：——

  日期：——
• CARM1 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20170283440A1

  公开（公告）日：2017-10-05

  Provided herein are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is an optionally substituted 6,5-bicyclic heteroaryl ring system comprising 2 to 5 nitrogen atoms, inclusive, wherein the point of attachment is provided on the 6-membered ring of the 6,5-bicyclic heteroaryl ring system, and wherein the 6-membered ring is further substituted with a group of formula -L 1 -R 3 , wherein L 1 and R 3 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.
• US8648103B2
  申请人：——

  公开号：US8648103B2

  公开（公告）日：2014-02-11